> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA FY 2027 Appropriation Report Analyzed
- URL: https://www.fdaweb.com/fda-fy-2027-appropriation-report-analyzed/
- Published: 2026-06-24T12:00:00.000Z
- Updated: 2026-09-14T13:41:51.000Z
- Author: David McFarland
- Tags: FDA Policy/General, Drugs, #legacy-id-D5161365

In the first of three planned online posts on FDA’s FY 2027 Appropriations Report, approved by the House Appropriations Committee to explain its agency funding bill, eight Hyman, Phelps & McNamara lawyers say the report “reflects a Congress eager to shape FDA’s regulatory priorities — from promoting artificial intelligence (AI)-driven efficiencies and strengthening foreign inspection programs to restricting clinical trial data from covered nations and addressing women’s health initiatives. Writing in their firm’s *FDA Law* Blog, the attorneys [say](https://www.thefdalawblog.com/2026/06/riders-on-the-storm-part-1-what-the-fy2027-appropriations-report-means-for-fda/?utm%5Fsource=rss&utm%5Fmedium=rss&utm%5Fcampaign=riders-on-the-storm-part-1-what-the-fy2027-appropriations-report-means-for-fda) the appropriations bill includes provisions that preclude the use of funds for animal research and human embryo research.

The appropriations report contains 143 FDA-related riders, the attorneys write, ranging from support for research and product approvals for specific diseases to clinical trial recommendations, international inspection requirements, and animal testing prohibitions.

A few of the themes the authors call attention to are:

- provisions “ordering” the agency to take specific actions with the expectation that agencies will comply, even though the provisions do not have the force of law;
- alignment with Trump administration priorities for deregulation, AI-driven efficiency in the approval process, and streamlining product review pathways;
- reflecting congressional regulatory priorities centered on diversity in clinical research and the health impacts of medical products on women and minorities, issues that are in tension with administration views;
- cross-product provisions involving AI, foreign inspections, China’s role in technology and clinical research, clinical trials, and women’s health.

The lawyers say they will produce additional posts on the report’s drug-specific provisions, including biosimilars, accelerated approvals, and other key areas of pharmaceutical regulation, and on everything else in the appropriations report, including medical devices and outsourcing.